Saturday, September 22, 2018 12:15:12 AM
If your point is that AVXL is capable of Astronomical Market Cap growth as Arrowhead Pharma I agree. But your chart is not effective in illustrating that fact. No other company could quite as directly illustrate the lows, rise, falls and subsequent vindication by Market Cap as ARWR. Your chart is actually meaningless in this regard as it charts stock price with over many years bears little to no correlation to market cap.
If one examines the Market Cap graph of ARWR and AVXL they are almost identical, with the exception that ARWR finally got market recognition.
2-11-2013 ARWR market cap was $30 million then it rose spectacularly in a short amount of time to 13 months 3-3-2014 to $1,090 Mil ($1.09 Bil) then fell back to $201 Mil on 2-10-2016 after doubling to $400 mil in 8 months fell back to where AVXL is today $110 mil on 7-17-2017 in the last 14 months it has risen 16X 1600% a 16 bagger in just one year same as AVXl is capable of on "Market Recognition" Arrowhead is a Phase II clinical stage company with no approved products. ARWR market cap is now one year later $1600 Mil ($1.6 Bil) Stock price charts do not show the growth of a company well because they do not account for share structure, the number of shares outstanding this is extremely exaggerated in charts of many years.
AVXL has the potential of ARWR type rapid market cap appreciation and then SOME!
At some point, the AVXL Market Cap chart might look like ARWR from July 2017 to today.
LOOK at the chart, the parallels to AVXL are uncanny:
ARWR:
https://www.macrotrends.net/stocks/charts/ARWR/arrowhead-pharmaceuticals/market-cap
AVXL:
https://www.macrotrends.net/stocks/charts/AVXL/anavex-life-sciences/market-cap
If one examines the Market Cap graph of ARWR and AVXL they are almost identical, with the exception that ARWR finally got market recognition.
2-11-2013 ARWR market cap was $30 million then it rose spectacularly in a short amount of time to 13 months 3-3-2014 to $1,090 Mil ($1.09 Bil) then fell back to $201 Mil on 2-10-2016 after doubling to $400 mil in 8 months fell back to where AVXL is today $110 mil on 7-17-2017 in the last 14 months it has risen 16X 1600% a 16 bagger in just one year same as AVXl is capable of on "Market Recognition" Arrowhead is a Phase II clinical stage company with no approved products. ARWR market cap is now one year later $1600 Mil ($1.6 Bil) Stock price charts do not show the growth of a company well because they do not account for share structure, the number of shares outstanding this is extremely exaggerated in charts of many years.
AVXL has the potential of ARWR type rapid market cap appreciation and then SOME!
At some point, the AVXL Market Cap chart might look like ARWR from July 2017 to today.
LOOK at the chart, the parallels to AVXL are uncanny:
ARWR:
https://www.macrotrends.net/stocks/charts/ARWR/arrowhead-pharmaceuticals/market-cap
AVXL:
https://www.macrotrends.net/stocks/charts/AVXL/anavex-life-sciences/market-cap
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
